Anti-seizure efficacy of perampanel in two established rodent models of early-life epilepsy
NS Roberts, MJ Handy, Y Ito, K Hashimoto… - Epilepsy & Behavior, 2023 - Elsevier
Early-life seizures can be refractory to conventional antiseizure medications (ASMs) and can
also result in chronic epilepsy and long-term behavioral and cognitive deficits. Treatments
targeting age-specific mechanisms contributing to epilepsy would be of clinical benefit. One
such target is the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)
subtype of excitatory glutamate receptor, which is upregulated in the developing brain.
Perampanel is a non-competitive, selective AMPAR antagonist that is FDA-approved for …
also result in chronic epilepsy and long-term behavioral and cognitive deficits. Treatments
targeting age-specific mechanisms contributing to epilepsy would be of clinical benefit. One
such target is the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)
subtype of excitatory glutamate receptor, which is upregulated in the developing brain.
Perampanel is a non-competitive, selective AMPAR antagonist that is FDA-approved for …